menu close arrow_back_ios person_add home


Ze względu na dynamicznie rozwijający się rynek suplementów diety w Polsce oraz prawo wymagające jedynie informowania o składzie suplementów, rozpoczynamy cykl monografii tych produktów medycznych, z którymi mogą spotkać się dietetycy i osoby profesjonalnie zajmujące się żywieniem człowieka.



Bibliografia do monografii:

  1. Audy J., Mathieu O., Belvis J., Tompkins T.A., Transcriptomic response of immune signalling pathways in intestinal epithelial cells exposed to lipopolysaccharides, Gram-negative bacteria or potentially probiotic microbes, "Benef Microbes."3(4), 2012, 273–286.
  2. Agarwal K.N., Bhasin S.K., Feasibility studies to control acute diarrhoea in children by feeding fermented milk preparations Actimel and Indian Dahi, "Eur J Clin Nutr." 56, 2002, 56–59.
  3. Beausoleil M., Fortier N., Guénette S., L’ecuyer A., Savoie M., Franco M. et al., Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial, "Can J Gastroenterol J Can Gastroenterol." 21(11), 2007, 732–736.
  4. Benes Z. et al., Probiotic Combination for IBS. A Pilot Clinical Study, "Nutrafoods." 5(1), 2006, 20–27.
  5. Bielanski W. et al., Enhancement of Helicobacter pylori eradication rate in Polish patients by the use of commercially available probiotics. 2003.
  6. Boge T., Rémigy M., Vaudaine S., Tanguy J., Bourdet-Sicard R., van der Werf S., A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials, "Vaccine" 27(41), 2009, 5677–5684.
  7. Cazzola M., Tompkins T.A., Matera M.G., Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection, "Ther Adv Respir Dis." 4(5), 2010, 259–270.
  8. Cazzola M., Pham-Thi N., Kerihuel J.C., Durand H., Bohbot S., Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study, "Ther Adv Respir Dis." 4(5), 2010, 271–278.
  9. Culpepper T., Christman M.C., Nieves C., Specht G.J., Rowe C.C., Spaiser S.J., Ford A.L., Dahl W.J., Girard S.A., Langkamp-Henken B., Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial, "Benef Microbes." 2016, 7(3), 327–336.
  10. Dykstra N.S., Hyde L., Adawi D., Kulik D., Ahrne S., Molin G. et al., Pulse probiotic administration induces repeated small intestinal Muc3 expression in rats, "Pediatr Res. march" 69(3), 2011, 206–211.
  11. Easo J., Measham J., Munroe J., Green-Johnson J., Immunostimulatory Actions of Lactobacilli: Mitogenic Induction of Antibody Production and Spleen Cell Proliferation by Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus acidophilus, "Food and Agricultural Immunology" 14(1), 2002, 73–83.
  12. FEEDAP panel, Technical Guidance: "Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance” by the EFSA Panel on Additives and Products or Substances used in Animal Feed (2012).
  13. Fernández J., Acevedo J., Castro M., Garcia O., de Lope C.R., Roca D., Pavesi M., Sola E., Moreira L., Silva A., Seva-Pereira T., Corradi F., Mensa J., Ginès P., Arroyo V., Prevalence and risk factors of infections by multiresistant bacteria in crirrhosis: a prospective study, "Hepatology" 55(5), 2012, 1551–1561.
  14. Grąt M., Wronka K.M., Lewandowski Z., Grąt K., Krasnodębski M., Stypułkowski J. i in., Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial, "Clin Nutr Edinb Scotl." 36(6), 2017, 1530–1539.
  15. Godwin N., Hyde L., Mack D., Intestinal mucin gene modulation in vivo using orally administered probiotic bacteria, "J Ped Gastroenterol Nutr." 41(4), 2005, 558–559.
  16. Jandu N., Zeng Z.J., Johnson-Henry K.C., Sherman P.M., Probiotics prevent enterohaemorrhagic Escherichia coli O157:H7-mediated inhibition of interferon-gamma-induced tyrosine phosphorylation of STAT-1, "Microbiol Read Engl." 155(Pt 2), 2009, 531–540.
  17. Johnson-Henry K.C., Hagen K.E., Gordonpour M., Tompkins T.A., Sherman P.M., Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells, "Cell Microbiol." 9(2), 2007, 356–367.
  18. Kapil S., Duseja A., Sharma B.K., Singla B., Chakraborti A., Das A., Ray P., Dhiman R.K., Chawla Y., Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease, "J Gastroenterol Hepatol." 31(1), 2016, 213–221.
  19. Kim B.C., Shin A., Hong C.W., Sohn D.K., Han K.S., Ryu K.H., Park B.J., Nam J.H., Park J.W., Chang H.J., Choi H.S., Kim J., Oh J.H., Association of colorectal adenoma with components of metabolic syndrome, "Cancer Causes Control." 23(5), 2012, 727–735.
  20. Kocian J., Further possibilities in the treatment of lactose intolerance-lactobacilli, "Prakticky Lekar." 74, 1994, 212–214.
  21. Kostrzynska M. et al., The effect of probiotic organisms on the adhesion of Escherichia coli O157:H7 to intestinal epithelial cells. Presented at the 4th Food Network meeting, Lacombe, Alberta, Canada 2002.
  22. Langkamp-Henken B., Rowe C.C., Ford A.L., Christman M.C., Nieves C., Khouri L., Specht G.J., Girard S.A., Spaiser S.J., Dahl W.J., Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study, "Br J Nutr." 14, 113(3), 2015, 426–434.
  23. MacPherson C.W., Shastri P., Mathieu O., Tompkins T.A., Burguière P., Genome-Wide Immune Modulation of TLR3-Mediated Inflammation in Intestinal Epithelial Cells Differs between Single and Multi-Strain Probiotic Combination, "PloS One" 12(1), 2017, 0169847.
  24. Manzano S., De Andrés J., Castro I., Rodríguez J.M., Jiménez E., Espinosa-Martos I., Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial, "Benef Microbes." 24, 8(4), 2017, 569–578.
  25. Maurice J., Manousou P., Non-alcoholic fatty liver disease, "Clin Med (Lond)" 18(3), 2018, 245–250.
  26. Merenstein D., Murphy M., Fokar A., Hernandez R.K., Park H., Nsouli H. et al., Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial, "Eur J Clin Nutr." 64(7), 2010, 669–677.
  27. Quarashi M.N. et al., The Gut-adherent micro biota of PSC-IBD is distinct to that of IBD, "Gut" 66, 2017, 611–619.
  28. Poeta M., Pierri L., Vajro P., Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease, "Children (Basel)" 2, 2017, 4(8).
  29. Ramarao N., Sanchis V., The pore-forming haemolysins of bacillus cereus: a review, "Toxins (Basel)" 7, 5(6), 2013, 1119–1139.
  30. Raszeja-Wyszomirska J., Lawniczak M., Marlicz W., Miezyńska-Kurtycz J., Milkiewicz P., Non-alcoholic fatty liver disease--new view, "Pol Merkur Lekarski" 24(144), 2008, 568–571.
  31. Saltzman E.T., Palacios T., Thomsen M., Vitetta L., Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease, "Front Microbiol." 9, 2018, 61.
  32. Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S.C., Goulet J., Tompkins T.A., Probiotics reduce enterohemorrhagic Escherichia coli O157:H7 and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements, "Infect Immun." 73(8), 2005, 5183–5188.
  33. Schuijt T.J., Lankelma J.M., Scicluna B.P. et al., The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia, "Gut" 65, 2016, 575–583.
  34. Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A., Caprioli F., Bottiglieri L., Oldani A., Viale G., Penna G., Dejana E., Rescigno M., A gut-vascular barrier controls the systemic dissemination of bacteria, "Science" 13, 350(6262), 2015, 830.
  35. Udupa K.V., Brayden D.J., Winter D.C., Baird A.W., Hepatic gateways, "Expert Rev Gastroenterol Hepatol." 10(5), 2016, 61–63.
  36. Wiest R., Albillos A., Trauner M., Bajaj J.S., Jalan R., Targeting the gut-liver axis in liver disease, "J Hepatol." 67(5), 2017, 1084–1103.
  37. Wong V.W. et al.,: High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis, "Gut" 60, 2011, 829.
  38. Xie Y., Tu B., Zhang X., Bi J., Shi L., Zhao P., Chen W., Liu S., Xu D., Qin E., Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection, "Oncotarget" 22, 9(3), 2017, 3980–3995.
  39. Ziemniak W., Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics, "J Physiol Pharmacol Off J Pol Physiol Soc." 3, 2006, 123–141.
  40. Zhang T., Abel S., Abel Zur Wiesch P., Sasabe J., Davis B.M., Higgins D.E., Waldor M.K., Deciphering the landscape of host barriers to Listeria monocytogenes infection, "Proc Natl Acad Sci USA" 13, 114(24), 2017, 6334–6339.


Bibliografia do 2 komentarza:

  1. Doron S., Snydman D.R., Risk and Safety of Probiotics, „Clin Infect Dis.” 15(60), 2015, 129–134.
  2. Hill C. i wsp., Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriateuse of the term probiotic, „Nat Rev Gastroenterol Hepatol.” 11(8), 2014, 506–514.
  3. Jach M. i wsp., Probiotyki – aspekty funkcjonalne i technologiczne, „Post. Mikrobiol.” 52(2), 2013, 161–170.



O autorze

Mikołaj Kamiński


Sanprobi sp. z o.o. sp. k.

Wojciech Marlicz


Klinika Gastroenterologii PUM w Szczecinie